OCGN
Ocugen, Inc.·Healthcare
1.38
2.985%(+0.04)
Close PriceLast Updated: — ET
52W L: $0.8052W H: $2.73
OCGN NEWS
globenewswire.com
May 14
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), including the full exercise by the initial purchaser of its option to purchase an additional $15.0 million aggregate principal amount of the notes.
fool.com
May 13
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
globenewswire.com
May 13
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026.
zacks.com
May 8
Ocugen (OCGN) Upgraded to Buy: Here's Why
Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
May 6
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.
seekingalpha.com
May 5
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
